Study guide

12.3 Respiratory & Gastrointestinal Agents

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

12.3 Respiratory & Gastrointestinal Agents

Key Takeaways Explain This Topic AI

Inhaled beta-2 agonists relax airway smooth muscle through Gs-cAMP; current asthma guidance favors an inhaled corticosteroid-formoterol reliever over short-acting beta-agonist monotherapy for adolescents and adults.

Montelukast blocks the CysLT1 leukotriene receptor and carries a boxed warning for neuropsychiatric events; zileuton inhibits 5-lipoxygenase; tiotropium and ipratropium block airway M3 receptors.

Theophylline has a narrow therapeutic index and is cleared by CYP1A2, so ciprofloxacin can cause theophylline toxicity with seizures and arrhythmias.

Proton pump inhibitors irreversibly inhibit the parietal-cell H+/K+-ATPase; long-term use is linked to C. difficile infection, hypomagnesemia, vitamin B12 deficiency and fractures, and omeprazole reduces clopidogrel activation.

Ondansetron blocks 5-HT3 receptors and prolongs the QT interval; metoclopramide blocks D2 receptors and carries a boxed warning for tardive dyskinesia; loperamide abuse at high doses causes torsades de pointes.

Last updated: October 2026

12.3 Respiratory & Gastrointestinal Agents

The outline lists respiratory agents (bronchodilators, beta-2 agonists, leukotriene inhibitors, anticholinergics, steroids and biologics) and gastrointestinal agents (proton pump inhibitors, H2 blockers, antiemetics, motility agents and antidiarrheals). Podiatric surgeons manage patients with asthma and COPD, prescribe NSAIDs that need gastroprotection, treat postoperative nausea and constipation, and must recognize interactions with antibiotics.

Respiratory Agents

Class Examples Mechanism Key adverse effects and pearls

Short-acting beta-2 agonists Albuterol, levalbuterol Beta-2 (Gs) raises cAMP and relaxes airway smooth muscle Tremor, tachycardia, hypokalemia (used to shift K+ into cells in hyperkalemia)

Long-acting beta-2 agonists Salmeterol, formoterol Same, with longer duration Not used as monotherapy in asthma because of increased asthma-related deaths; paired with inhaled corticosteroids

Inhaled corticosteroids Fluticasone, budesonide, beclomethasone Suppress airway inflammation (NF-kB transrepression) Oral candidiasis and dysphonia (rinse after use); high doses affect bone density

Systemic corticosteroids Prednisone, methylprednisolone Broad anti-inflammatory action Hyperglycemia, infection, poor wound healing

Muscarinic antagonists Ipratropium (short-acting), tiotropium and umeclidinium (long-acting) Block airway M3 receptors Dry mouth, urinary retention; mainstay of COPD therapy

Leukotriene modifiers Montelukast , zafirlukast (CysLT1 receptor antagonists); zileuton (5-lipoxygenase inhibitor) Block leukotriene-mediated bronchoconstriction Montelukast boxed warning for neuropsychiatric events ; zileuton hepatotoxicity

Methylxanthine Theophylline Phosphodiesterase inhibition and adenosine antagonism Narrow therapeutic index ; cleared by CYP1A2 , so ciprofloxacin and cimetidine cause toxicity (seizures, arrhythmias)

PDE4 inhibitor Roflumilast Raises cAMP in inflammatory cells Weight loss, diarrhea; severe COPD with chronic bronchitis

Biologics Omalizumab (anti-IgE); mepolizumab, reslizumab (anti-IL-5); benralizumab (anti-IL-5 receptor); dupilumab (anti-IL-4 receptor alpha); tezepelumab (anti-TSLP) Target Th2 and eosinophilic inflammation Severe asthma phenotypes; injection reactions; anaphylaxis risk with omalizumab

Asthma and COPD strategy. For adolescents and adults, international asthma guidance no longer recommends short-acting beta-agonist treatment alone. It prefers as-needed low-dose inhaled corticosteroid-formoterol as the reliever, with daily controller therapy added by severity. COPD therapy centers on long-acting bronchodilators (LAMA and/or LABA). Inhaled corticosteroids are added mainly for frequent exacerbations with higher blood eosinophil counts.

Perioperative point. Patients with asthma should bring their reliever inhaler. Non-selective beta-blockers can precipitate bronchospasm (10.3), and some patients with aspirin-exacerbated respiratory disease develop bronchospasm with any COX-1-inhibiting NSAID.

  • Gastrointestinal Agents
  • Acid Suppression and Mucosal Protection

Drug Mechanism Key points

Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) Prodrugs activated in the acid canaliculus that irreversibly bind the H+/K+-ATPase Take 30–60 minutes before breakfast; long-term risks include C. difficile infection , hypomagnesemia , vitamin B12 deficiency , fracture risk and acute interstitial nephritis; omeprazole and esomeprazole inhibit CYP2C19 , reducing clopidogrel activation

H2 receptor antagonists (famotidine, cimetidine) Block parietal cell H2 receptors Cimetidine inhibits several CYP enzymes and has antiandrogenic effects; ranitidine was withdrawn in 2020 because of NDMA contamination

Antacids (calcium carbonate, magnesium and aluminum hydroxide) Neutralize acid Chelate fluoroquinolones and tetracyclines ; magnesium causes diarrhea, aluminum causes constipation

Sucralfate Forms a protective barrier over ulcer bases in acid Binds fluoroquinolones and other drugs

Misoprostol PGE1 analog; increases mucus and bicarbonate, reduces acid Prevents NSAID ulcers; contraindicated in pregnancy (uterine contractions)

NSAID gastroprotection. Patients at higher GI risk (older age, prior ulcer, anticoagulants or steroids) who need an NSAID should take a PPI or misoprostol, or use a COX-2-selective agent with its cardiovascular trade-offs (11.3).

Antiemetics

  • Class Examples Adverse effects
  • 5-HT3 antagonists Ondansetron, granisetron QT prolongation , headache, constipation

D2 antagonists Metoclopramide, prochlorperazine, promethazine Extrapyramidal effects ; metoclopramide carries a boxed warning for tardive dyskinesia with long-term use; IV promethazine can cause severe tissue injury and gangrene with extravasation or intra-arterial injection

  • NK1 antagonists Aprepitant, fosaprepitant CYP3A4 interactions
  • Corticosteroid Dexamethasone Transient hyperglycemia, which matters in diabetic surgical patients
  • Anticholinergic Transdermal scopolamine Confusion and urinary retention in older adults
  • Cannabinoids Dronabinol, nabilone Used for chemotherapy-induced nausea (12.5)

Postoperative nausea prevention often combines drugs from different classes.

Motility, Laxatives and Opioid-Induced Constipation

Prokinetics: metoclopramide (D2 blockade with 5-HT4 effects) and erythromycin (motilin receptor agonist) speed gastric emptying in diabetic gastroparesis .

Laxatives: osmotic (polyethylene glycol, lactulose), stimulant (senna, bisacodyl) and stool softeners (docusate). Prescribe a bowel regimen with every postoperative opioid, because no tolerance develops to opioid constipation (11.3).

Peripherally acting mu-opioid antagonists: methylnaltrexone, naloxegol and naldemedine reverse opioid-induced constipation without reversing analgesia, because they do not cross the blood-brain barrier.

Antidiarrheals

Loperamide: a peripheral mu-opioid agonist. Very high doses (misuse) cause QT prolongation and torsades de pointes .

Diphenoxylate-atropine: atropine is added to discourage abuse.

Bismuth subsalicylate: causes black stool and tongue; it contains salicylate , which matters with anticoagulants and aspirin allergy.

Avoid antimotility drugs in suspected C. difficile colitis or bloody infectious diarrhea, because slowing transit can worsen toxin-mediated disease.